FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

Results from Blue Earth Diagnostics’ head-to-head study have been published in the European Journal of Nuclear Medicine and Molecular Imaging and were just presented at the 2026 ASCO Genitourinary ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...

An oncologist explains the situations when doctors recommend getting screened for colorectal cancer before age 45.

Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

The integration of genomic testing into cancer screening enables diagnostics to break away from conventional, one-size-fits-all protocols.

Some sit quietly in the body for decades. Only a fraction ever become life threatening. The problem is that once an ...

This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.

DeepHealth is introducing in Europe its cloud-first integrated portfolio combining clinical AI, multi-modality viewing and reporting, which is designed to improve outcomes, efficiency and access to ca ...